Descrizione del progetto
Spianare la strada a innovativi progressi nella biologia degli adenovirus
I vettori basati su adenovirus sono promettenti per il trasferimento genico e la vaccinazione, e offrono un potenziale valore traslazionale e commerciale. La loro efficacia, tuttavia, dipende dai ceppi a bassa sieroprevalenza, che sono fondamentali per la progettazione dei vettori. La comprensione approfondita di questi ceppi rimane però una sfida, che ostacola la loro applicazione in contesti terapeutici. Con il sostegno del programma di azioni Marie Skłodowska-Curie, il progetto INVECTA promuove la ricerca collaborativa su nuovi vettori di adenovirus a bassa sieroprevalenza. L’obiettivo è quello di comprendere le interazioni vettore-ospite, il tropismo e le risposte immunitarie. Concentrandosi sulla formazione dei ricercatori e sulla creazione di collaborazioni a lungo termine, INVECTA mira a far progredire la terapia genica e la vaccinazione contro il cancro. Attraverso sforzi interdisciplinari e la condivisione delle conoscenze, il progetto cerca di definire protocolli e metodologie per applicazioni adenovirali sicure ed efficaci.
Obiettivo
Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establishing foundation for long term collaboration. As the use of adenoviral based platforms becomes widespread there is a pressing need to develop protocols and methodologies to define the full complement of adenovirus-host interactions, the “adenoviral interactome”, that may limit efficacy and compromise safety. Within INVECTA we aim to increase our understanding of novel low seroprevalence adenovirus vectors with respect to infectivity, structure, stability, receptor usage, tropism, and the interaction with the blood and immune system. This knowledge will allow us to evaluate novel low seroprevalence vectors at the pre-clinical level in areas of unmet clinical need, namely cancer gene therapy and vaccination. INVECTA presents an interdisciplinary and intersectoral network in basic and translational adenovirus research which will foster transfer of knowledge, skills and technology, as well as enable training in the field of basic and applicative adenovirus biology. To maximize knowledge sharing, INVECTA will second researchers within consortium, organize internal workshops and training sessions, and strongly encourage participation in specialized workshops, schools and conferences according to the open science model.
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Meccanismo di finanziamento
HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff ExchangesCoordinatore
10000 Zagreb
Croazia